Bleomycin

Essential medicine status

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc | ATC codes: L01DC01

Indication	Kaposi sarcoma of unspecified primary site ICD11 code: 2B57.Z
INN	Bleomycin
Medicine type	Chemical agent
List type	Complementary
Formulations	**Parenteral > General injections > unspecified:** 15000 IU in vial (as sulfate)
EML status history	First added in 1979 (TRS 641) Changed in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Bleomycin
DrugBank	Bleomycin

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended that the strength of bleomycin powder for injection be expressed in IU and not mg, to reflect dosing protocols.